Impel press release
Witryna5 maj 2024 · SEATTLE, May 5, 2024 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced an expanded role of Adrian Adams, … Witryna22 lut 2024 · SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing …
Impel press release
Did you know?
Witryna7 wrz 2024 · SEATTLE, Sept. 07, 2024 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that it … Witryna18 sty 2024 · This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential clinical benefits of Trudhesa™, the market opportunities of Trudhesa within the migraine market, the speed of uptake and …
Witryna24 mar 2024 · Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update. Mar 24, 2024. PDF Version. … Witryna16 sie 2024 · SEATTLE, August 16, 2024 — Impel NeuroPharma (NASDAQ: IMPL), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS, today reported …
Witryna15 sie 2024 · SEATTLE, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the second quarter ended June 30, 2024 … Witryna11 kwi 2024 · Highlights Include Multiple Presentations Addressing Safety and Efficacy of TrudhesaSEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals... Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2024 American Academy of Neurology Annual Meeting - NXT Life …
WitrynaThe Impel Platform; Merchandising; Communication; Imaging; Enterprise Developer Cloud; Integrations; Solutions. Dealership Groups; Local Auto Dealers; Specialty …
Witryna16 maj 2024 · SEATTLE, May 16, 2024 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today reported financial … nothing special to doWitryna22 lut 2024 · SEATTLE, March 03, 2024 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company … nothing special vWitryna25 kwi 2024 · SEATTLE, April 25, 2024 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is changing its name to Impel Pharmaceuticals. how to set up sonos beam sound barWitryna9 wrz 2024 · Sep 09, 2024. PDF Version. SEATTLE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage … how to set up sonos ampWitryna19 lip 2024 · SEATTLE, July 19, 2024 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing … nothing springs to mindWitryna2 cze 2024 · SEATTLE, June 2, 2024 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of … nothing special norm macdonaldWitryna7 wrz 2024 · SEATTLE, Sept. 07, 2024 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing … nothing stake nothing draw